Duke University creates EyeSyn virtual eyes that mimic the real human eye movement when focusing on various visual stimuli.

ACADEMIC PAPER Abstract “In recent years, the electrical and/or electronic architecture of vehicles has been significantly evolving. The new generation of cars demands a considerable amount of computational power due to a large number of safety-critical applications and driver-assisted functionalities. Consequently, a high-performance computing unit is required to provide the demanded power and process these... » read more

The post E/E Architecture Synthesis: Challenges and Technologies appeared first on Semiconductor Engineering.

Acoustic signals produced during manufacturing provide real-time information about the form and quality of laser-induced graphene

The post Listening to graphene yields clues to its structure appeared first on Physics World.

The key to fabricate single-atom catalysts is the confinement of transition metal atoms in the precursor, which remains a critical challenge. Addressing this critical challenge, researchers recently proposed clicking confinement strategy as a new synthesis methodology towards the fabrication of single-atom catalysts. This strategy breaks the restrictions on molecular size or symmetry and significantly broadens the fabrication approaches. It also is of great specificity, ensuring the precise construction of single-atom sites with unique structures or distributions.

Join the audience for a live webinar on 20 April 2022 sponsored by Hiden Analytical, The Royal Society of Chemistry and Cell Press, in partnership with The Electrochemical Society

The post Electrification and decarbonization of chemical synthesis appeared first on Physics World.

Nanomachines, also known as molecular machines or nanites, are molecular robots not larger than a strand of human hair. They can be programmed to carry out tasks in biological systems. Biologists frequently use these molecular machines to perform DNA replication and ATP synthesis tasks. Nanorobotics is one of the most

March 2022 By Ana Clara Ribeiro, Intellectual Property attorney, Curitiba, Brazil The Korean boy band BTS is one of the most successful groups of all time....

Three pillars of a methodology that focuses on bug prevention.

The post Shifting The Design Paradigm To Improve Verification Efficiency appeared first on Semiconductor Engineering.

PotionLabs, the developers of the new risk management layer Potion Protocol, have announced the launch of the Potion Unlock NFT auction. Those who purchase NFTs in the auction will be able to participate in the Potion Unlock game, working with other community members to release the Potion Protocol into the public domain. With this one-of-a-kind strategy based on “aggressive decentralization”, Potion Labs seeks to avoid the dangers of a traditional project launch and to maximize community involvement. 

The mechanics of the game are simple. The codebase of the entire project has been stored in IPFS and protected with a strong password. This password has then been split into segments of various lengths and will be distributed across 10,000 unique NFTs.

In order for the code to be finally decrypted and made public, participants will have to collaborate to bring enough of the pieces together. The game itself is totally open-ended: players will have to self-coordinate - without the input of Potion Labs - to find their own solution to the problem. 

Once the protocol's file is decrypted and released into the public domain, a community with ‘skin in the game' and web3 operational capabilities will have been formed. This community will then have power and stewardship over the future of the Potion Protocol as a public good.

How Can Players Participate in the Potion Unlock Game? 

The majority of Potion NFTs will be sold to the public via a Dutch-style auction starting 14^th March (whitelisting already live) where high profile DeFi and NFT participants are expected to take part. 

To strengthen the participating community, two Potion NFT rarities (Kelly Knights and Wise Wizards), have already been distributed through a $12M private sale last January. These were bought by prominent DeFi players such as Polychain, Placeholder, Maven 11, Pantera, The LAO, MetaCartel, Parafi, Spartan, Robert Leshner, Fernando Martinelli, Synthetix founders, Crypto Plaza, Roble VC, CULTUR3, Lemniscap, Zee and beToken Capital, among others.

Finally, Potion's early community members (OGs or Original Gangsters), also received a generous allocation of Potion OG NFTs at no cost, in recognition for their early community support and inspiration. A significant number of OG NFTs have also been made available in the form of airdrops to 1,000 leading members of prominent DAOs, with the goal of building a high-quality community around the project. 

What is the Symbolism of the Potion NFT Design? 

Potion Unlock NFTs commemorate the release of the Lab's Kelly Machine and its key technical breakthrough: the synthesis of the Kelly Criterion into a bonding curve. To celebrate this, each NFT symbolically and artistically represents a different insurance contract. Various characteristic artifacts are used in each NFT to represent the specific parameters of an insurance contract. 

The collection of NFTs is made up of 10,000 unique pieces, which together embody one of the first artistic renderings of a financial product as well as providing a dictionary of Kelly Criterion bonding curves. Importantly, Potion NFTs are digital collectibles, not financial instruments: only the original NFT minters can participate in the Potion Unlock game. 

What are Potion NFT Rarities?

There are 6 NFT types or “rarities” in the game, each with a different “decryption power”, giving the various players different capabilities and powers. Each NFT rarity will also have a different “redundancy” level, so no single holder can block the resolution of the game. 

What is the Motivation Behind the Project?

PotionLabs is seeking to accomplish several goals with this launch model. The developers are deep believers in decentralization and designed Potion Unlock to transfer control of the Potion Protocol to the community. In this way, the approach delivers “aggressive decentralization' and avoids power becoming concentrated in the hands of the few, ensuring that it is instead spread across the community.

This form of protocol release is also meant to create a commercially viable way for PotionLabs to continue to finance its research work while operating within clear regulatory guidelines. PotionLabs also hopes this novel release model can be of use for other Web3 projects.

What do the Team Have to Say?

“We are excited about the opportunity to introduce a new class of services built from the ground up by the community for the community. We believe in a community-first approach to creating radically new technology aimed at helping users in DeFi manage the risk of their assets in a simple and reliable way,” said Guillem Mosquera, PotionLabs Co-founder, and CTO.

"We are deeply grateful to the community around the project who decided to support our vision and team. We are experimenting with new approaches to open source development for web3 and are lucky to have a visionary community willing to fuel and support our exploration. We are excited for them to continue playing a key role in the project's community," said Jordi Muñoz, PotionLabs Co-founder and CEO.

"Extremely sophisticated on the backend, surprisingly simple on the frontend, Potion ushers in a new era of risk management for DeFi liquidity providers (LPs) and consumers. By using the Kelly Criterion, Potion allows LPs to optimally price options according to their desired risk and yield parameters. Then, by aggregating all individual LP curves, Potion offers the best-priced options to the consumer. When people say DeFi 2.0, Potion sits at the top of that list", said Chris Burniske, Partner at Placeholder.

About Potion Labs

PotionLabs is a web3-native research and software development company that has developed a robust risk management layer for crypto assets, the Potion Protocol. It pioneers a new risk pricing model based on the Kelly Criterion, which results in long-term survival mathematical expectations for LPs, and deeper, more reliable liquidity markets for users. The release of the Protocol's code is launching shortly through the Potion NFT Unlock game. More on PotionLabs here: https://potion.fi & https://potion.auction 

PotionLabs, the developers of the new risk management layer Potion Protocol, have announced the launch of the Potion UnlockNFT auction. Those who purchase NFTs in the auction will be able to participate in the Potion Unlock game, working with other community members to release the Potion Protocol into the public domain. With this one-of-a-kind strategy based on “aggressive decentralization”, Potion Labs seeks to avoid the dangers of a traditional project launch and to maximize community involvement. 

The mechanics of the game are simple. The codebase of the entire project has been stored in IPFS and protected with a strong password. This password has then been split into segments of various lengths and will be distributed across 10,000 unique NFTs.

In order for the code to be finally decrypted and made public, participants will have to collaborate to bring enough of the pieces together. The game itself is totally open-ended: players will have to self-coordinate - without the input of Potion Labs - to find their own solution to the problem. 

Once the protocol's file is decrypted and released into the public domain, a community with ‘skin in the game' and web3 operational capabilities will have been formed. This community will then have power and stewardship over the future of the Potion Protocol as a public good.

How Can Players Participate in the Potion Unlock Game? 

The majority of Potion NFTs will be sold to the public via a Dutch-style Potion NFT auction, from March 14 until March 24 starting February 28th, where high profile DeFi and NFT participants are expected to take part. Whitelisting is already live.

To strengthen the participating community, two Potion NFT rarities (Kelly Knights and Wise Wizards), have already been distributed through a $12M private sale last January. These were bought by prominent DeFi players such as Polychain, Placeholder, Maven 11, Pantera, The LAO, MetaCartel, Parafi, Spartan, Robert Leshner, Fernando Martinelli, Synthetix founders, Crypto Plaza, Roble VC, CULTUR3, Lemniscap, Zee, and beToken Capital, among others.

Finally, Potion's early community members (OGs or Original Gangsters), also received a generous allocation of Potion OG NFTs at no cost, in recognition for their early community support and inspiration. A significant number of OG NFTs have also been made available in the form of airdrops to 1,000 leading members of prominent DAOs, with the goal of building a high-quality community around the project. 

What is the Symbolism of the Potion NFT Design? 

Potion Unlock NFTs commemorate the release of the Lab's Kelly Machine and its key technical breakthrough: the synthesis of the Kelly Criterion into a bonding curve. To celebrate this, each NFT symbolically and artistically represents a different insurance contract. Various characteristic artifacts are used in each NFT to represent the specific parameters of an insurance contract. 

The collection of NFTs is made up of 10,000 unique pieces, which together embody one of the first artistic renderings of a financial product as well as providing a dictionary of Kelly Criterion bonding curves. Importantly, Potion NFTs are digital collectibles, not financial instruments: only the original NFT minters can participate in the Potion Unlock game. 

What are Potion NFT Rarities?

There are 6 NFT types or “rarities” in the game, each with a different “decryption power”, giving the various players different capabilities and powers. Each NFT rarity will also have a different “redundancy” level, so no single holder can block the resolution of the game. 

What is The Motivation Behind the Project?

PotionLabs is seeking to accomplish several goals with this launch model. The developers are deep believers in decentralization and designed Potion Unlock to transfer control of the Potion Protocol to the community. In this way, the approach delivers “aggressive decentralization' and avoids power becoming concentrated in the hands of the few, ensuring that it is instead spread across the community.

This form of protocol release is also meant to create a commercially viable way for PotionLabs to continue to finance its research work while operating within clear regulatory guidelines. PotionLabs also hopes this novel release model can be of use for other Web3 projects.

What Does the Team Have to Say?

“We are excited about the opportunity to introduce a new class of services built from the ground up by the community for the community. We believe in a community-first approach to creating radically new technology aimed at helping users in DeFi manage the risk of their assets in a simple and reliable way,” said Guillem Mosquera, PotionLabs Co-founder, and CTO.

"We are deeply grateful to the community around the project who decided to support our vision and team. We are experimenting with new approaches to open source development for web3 and are lucky to have a visionary community willing to fuel and support our exploration. We are excited for them to continue playing a key role in the project's community," said Jordi Muñoz, PotionLabs Co-founder and CEO.

"Extremely sophisticated on the backend, surprisingly simple on the frontend, Potion ushers in a new era of risk management for DeFi liquidity providers (LPs) and consumers. By using the Kelly Criterion, Potion allows LPs to optimally price options according to their desired risk and yield parameters. Then, by aggregating all individual LP curves, Potion offers the best-priced options to the consumer. When people say DeFi 2.0, Potion sits at the top of that list", said Chris Burniske, Partner at Placeholder.

###

About Potion Labs

PotionLabs is a web3-native research and software development company that has developed a robust risk management layer for crypto assets, the Potion Protocol. It pioneers a new risk pricing model based on the Kelly Criterion, that results in long-term survival mathematical expectations for LPs and deeper, more reliable liquidity markets for users. The release of the Protocol's code is launching shortly through the Potion NFT Unlock game. More on Potion.Finance here: https://potion.fi & https://potion.auction

PotionLabs Contact

press@potion.fi

If you’re new to the world of psychedelics, this is a pretty incredible headline. If you’re well versed in the power of hallucinogens, then you’re probably glad that the medical world of today took yet another step to catch up. No matter how you look at it, progress is progress, and this is definitely progress. […]

The post Study Finds Psilocybin Therapy Has Long-Lasting Results appeared first on CBD Testers.

TOKYO, Mar 7, 2022 - (JCN Newswire) - Fujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data. Leveraging the world's fastest supercomputer "Fugaku,"(1) the new technology enables high-speed calculation of 20,000 variables of data within a single day and allows for the discovery of previously unknown causal relationships relating to drug resistance in cancer cells from 1,000 trillion different possibilities.
Fujitsu and TMDU applied this technology to gene expression level(2) data obtained from cancer cell lines in order to analyze drug resistance(3) against anticancer drugs, and succeeded in extracting a new causal mechanism of a previously unknown gene that suggests a cause of resistance to lung cancer drugs. The new technology is expected to contribute to the acceleration of drug discovery and the realization of cancer therapies individualized for each patient.
The technology was developed under the theme of "elucidation of the cause and diversity of cancer using large-scale data analysis and AI technology," an initiative supported by TMDU, Kyoto University and Fujitsu as part of the supercomputer Fugaku achievement acceleration program(4).

Background

Even if a patient receives a targeted cancer drug(5) therapy, the appearance of drug-resistant cancer cells represents an ongoing threat to full remission. The mechanism for how certain cancers become drug resistant remains unclear, however, and researchers continue to work on new methods of analysis that shed light on how cells that have multiple driver mutations(6) acquire drug resistance. In drug development and clinical trials involving drug repositioning(7), it is important to identify patients for whom drugs are anticipated to have an effect. However, the effectiveness of drugs may differ depending on the organ and the individual and variations in gene expression, and the number of patterns combining expression levels of multiple genes exceeds 1,000 trillion(8). A comprehensive search of all 20,000 genes in the human genome would thus take more than 4,000 years with a conventional computer and finding ways to accelerate the process represents a major challenge.

Newly developed technology

Fujitsu implemented parallel conditional and causal algorithms to maximize computational performance with the supercomputer Fugaku to analyze the human genome within a timeframe needed for practical research. By utilizing Fujitsu's "Wide Learning"(9) AI technology to extract combinations of potential genes relating to the emergence of drug resistance based on statistical information, Fujitsu developed a novel technology that makes it possible to conduct a comprehensive search within a day.

Results

As a result of running data of the Dependency Map (DepMap)(10) portal using this technology on the supercomputer Fugaku, Fujitsu and TMDU were able to search the entire human genome for conditions and causality within a single day and determine the genes that cause resistance to drugs used to treat lung cancer(11).

Comment from Prof. Seiji Ogawa, Graduate School of Medicine, Kyoto University

Promising technologies like Fujitsu's AI technology for scientific discovery ("Wide Learning") may one day contribute to the discovery of biomarkers, which represent an area of growing interest in drug development. The key to the success of new drug development is to identify patients who are expected to benefit from new drugs and conduct clinical trials. If the marker that predicts who will benefit from the drug is known, the cost of clinical trials can significantly be reduced and the probability of success by conducting individual clinical trials can be increased. From this point of view, pharmaceutical manufacturers and others are expected to be very interested in this technology. The fact that it has been implemented using Fugaku has also raised expectations.

Future Plans

Moving forward, Fujitsu and TMDU will conduct a multilayered and comprehensive analysis that combines various data including time axis and location data with the aim of accelerating medical research, including in the field of drug efficacy, as well as to shed light on the causes of cancer.
Fujitsu and TMDU will also collaborate in experimental research in the fields of drug discovery and medicine. TMDU will further utilize the technology developed in this research to promote research on strategies for intractable diseases such as cancer.

In addition to medical care, Fujitsu will utilize the new technology to resolve challenges in a variety of fields, including marketing, system operations and manufacturing.

Acknowledgements
This research was conducted as part of Ministry of Education, Culture, Sports, Science and Technology's Fugaku Achievement Acceleration Program "Understanding the Origin and Diversity of Cancer through Large-scale Data Analysis and Artificial Intelligence Technologies" (JPMXP 1020200102). A part of the research was conducted with the computational resources of supercomputer Fugaku (Issue #: hp 200138, hp 210167).

(1) Supercomputer "Fugaku":
A computer installed at RIKEN as a successor to the supercomputer "K." From June 2020 to November 3, it ranked first in 4 categories in the supercomputer rankings for 4 consecutive years. Full operation started on March 9, 2021.
(2) Gene expression level :
Amount of RNA copied from DNA (the same nucleic acid as DNA synthesized by transcription using some DNA sequences as templates).
(3) Drug resistance :
A phenomenon in which the effect of a drug weakens while the drug is being administered.
(4) Supercomputer Fugaku Achievement Acceleration Program :
Program started in May 2020 by the Ministry of Education, Culture, Sports, Science and Technology with the aim to achieve early results.
(5) Targeted drug :
A drug designed to act only on the molecule (protein, gene, etc.) that is causing the disease.
(6) Driver mutations :
A genetic mutation that directly causes the development or progression of cancer.
(7) Drug repositioning :
The application of existing drugs developed and approved for the treatment of one disease to the treatment of another disease.
(8) More than 1,000 trillion :
Even if the expression level of each gene is restricted to a combination of 50 major genes known to be related to cancer and the expression level of each gene is classified into 2 categories (e.g., "high" or "low" gene expression), the condition number is 2 to the power of 50, which exceeds 1,000 trillion.
(9) Wide Learning :
Official site "Hello, Wide Learning!"
(10) Dependency Map (DepMap) :
Data on the sensitivity and resistance of approximately 4,500 drugs to approximately 600 different cancer cell lines, provided by the American Broad Institute. Mutation information of cancer cell lines and expression data of all genes are included.
(11) Fujitsu and TMDU analyzed gene expression data from DepMap of approximately 300 cancer cell lines, sensitivity and resistance data of Gefitinib (molecularly targ eted drug used to treat lung cancer and other cancer types), and comprehensively searched for conditions and mechanisms of cancer cell lines that do not respond to Gefitinib. Fujitsu and TMDU identified conditions under which the expression levels of three transcription factors (genes that control gene transcription (synthesis of RNA)), ZNF516, E2F6, and EMX1, were low. In lung cancer cell lines that meet these conditions, a mechanism triggered by the transcription factors SP7 and PRRX1 was discovered as further potential causes of drug resistance in cancer cells (see reference image).

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
About Tokyo Medical and Dental University

Tokyo Medical and Dental University (TMDU) is Japan's only comprehensive medical university and graduate school, and has provided advanced medical treatment through a fusion of the medical and dental fields and worked to cultivate "professionals with knowledge and humanity." TMDU contributes to human health and the well-being of society by fostering outstanding healthcare professionals with a humane and global outlook.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comFujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data.